Jaguar Health’s (JAGX) Napo Pharmaceuticals issued a reminder that an abstract describing partial results of the independent and ongoing investigator-initiated trial of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with intestinal failure due to microvillus inclusion disease and short bowel syndrome, will be presented this coming Saturday, November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting taking place November 5-8, 2025 in Chicago. The results of the ongoing investigator-initiated proof-of-concept trial in the UAE demonstrate reduction of total parenteral support in pediatric intestinal failure patients ranging between 12% to 37%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health completes FDA Type C meeting on crofelemer trial
- Jaguar Health Reduces Royalty Interest with Stock Exchange
- Jaguar Health files to sell 2.62M shares of voting common stock for holders
- Jaguar Animal Health Secures Funding Through Private Placement
- Jaguar Health’s Napo providing crofelemer powder for use in two EAPs